Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Helix TCS (OTC: HLIX) CEO Zachary Venegas talks cannabis industry M&A in technology and security services. Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over […]
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original […]
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders. Dear Shareholder, Get […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
